The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a complex picture. While early earnings were impressive, the cessation of patents and the emergence of discounted alternatives have eroded the customer more info base. Consequently,